|
**Overview**: Chimerism Pre-Engraftment Panel**Introduction**: The Chimerism Pre-Engraftment Panel is a diagnostic tool designed to assess pre-transplant chimerism using whole blood samples. In India, pre-transplant baseline chimerism establishes recipient DNA profile for post-HSCT comparison in allogeneic transplants. High burden of hematological disorders requiring HSCT, with pre-testing essential for accurate engraftment monitoring. High morbidity from inadequate baseline in resource-limited centers leading to misinterpretation post-transplant. Per hematology practices aligned with ICMR guidelines, the test employs PCR for donor/recipient DNA quantification over 1-2 days with high accuracy, valuable for establishing reference. This diagnostic falls under pre-transplant evaluation and targets HSCT candidates, addressing accurate baseline to guide post-transplant monitoring. With elevated risks due to under-testing, the test supports public health efforts by enabling precise engraftment tracking. Its whole blood-based approach ensures reliable detection.**Other Names**: Chimerism Pre Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology, compliant with 2025 standards.**Historical Milestone**: Pre-transplant baseline standard; in India, essential in transplant protocols.**Purpose**: The test assesses 2 parameters including donor DNA to guide pre-engraftment chimerism, establish baseline, inform post-transplant comparison.**Test Parameters**: 1. Donor DNA, 2. Recipient DNA.**Pretest Condition**: No fasting required; patients should be pre-HSCT candidates.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on transplant indication, donor type, prior transfusions.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of inaccurate baseline including misinterpretation, benefits of pre-testing, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Baseline donor/recipient profiles established for post-transplant comparison, necessitating specialist input.**Specialist Consultation**: Transplant hematologists should be consulted for interpretation.**Additional Supporting Tests**: HLA typing for confirmation.**Test Limitations**: Pre-transplant only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, HSCT Studies India 2023. |
